Psoriasis (PsO)MEB@ZPMNCT07132333
Molecular Inflammation Board at the Center for Personalized Medicine
An observational study of Psoriasis (PsO) and Psoriasis Arthritis, run by University Hospital Tuebingen at 1 site in Germany.
Trial summary
Molecular Inflammation Board at the Center for Personalized Medicine Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Psoriasis (PsO), Psoriasis Arthritis, Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)
- What is being tested?
- Biologic Agent
- How many people
- 3,000 participants
- Where
- 1 siteGermany
- Study dates
- 16 Nov 2022to Nov 2032
- How long will I take part?
- 14 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: Patients with chronic inflammatory diseases and indication for therapy with biologic agents
Who may be able to join
- Chronic inflammatory disorder (PsO, PsA, SpA, IBD)
- Given informed consent
- 18 years of age
Who cannot join
- No capacity to consent
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Germany1 site, 1 recruiting
- Recruiting
University Hospital of Tübingen - Center for Personalized Medicine
Tübingen, 72076
Fee Schmitt, Dr., +4970712981240, zpm-meb@med.uni-tuebingen.de
About this study
Official title: The Molecular Inflammation Board at the Centers for Personalized Medicine at the University Hospitals of Freiburg, Heidelberg, Tübingen and Ulm - A Multicenter Prospective Observational Study
Molecular Inflammation Board at the Center for Personalized Medicine
Read the detailed description
Molecular Inflammation Board at the Center for Personalized Medicine
The study objectives are:
To ensure a prospective documentation of all patients who are referred to the Molecular Inflammation Board in routine clinical care To prospectively ensure the documentation of MEB patients with an emphasis to clinical outcome parameters and further response assessments (e.g. peripheral immunmonitoring, imaging parameters) To prospectively assess patient-reported outcome of MEB patients To evaluate compliance to MEB suggestions in routine clinical care
- Conditions
- Psoriasis (PsO), Psoriasis Arthritis, Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Spondylarthropathies
- Being tested
- Biologic Agent
- Keywords
- chronic inflammatory diseases, personalized medicine
- Medical subject headings
- Psoriasis, Inflammatory Bowel Diseases, Colitis, Ulcerative, Spondylarthropathies
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Biologic AgentBiological
Intervention with biologic agents
What is being measured
The primary outcome is the main question the study is designed to answer.
Therapy persistence
Duration of intervention with biological agent
Measured: Through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Aug 2025
- Study start16 Nov 2022
- Primary completionNov 2032 (estimated)
- Study completionNov 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Psoriasis (PsO)Studies of the same condition, open and under way.
- More trials run by University Hospital TuebingenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 3,000 participants (estimated)
- Target duration
- 14 Months
Sponsor and investigators
- Lead sponsor
- University Hospital Tuebingen
- Sponsor type
- University, hospital or other
- Collaborators
- University Hospital Freiburg, University Hospital Heidelberg, University Hospital Ulm
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07132333
- Sponsor's protocol ID
- 482/2022BO1
- Acronym
- MEB@ZPM
- Status last verified
- Aug 2025
- First submitted
- 11 Aug 2025
- Last updated
- 20 Aug 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 20 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Molecular Inflammation Board at the Centers for Personalized Medicine at the University Hospitals of Freiburg, Heidelberg, Tübingen and Ulm - A Multicenter Prospective Observational Study
- ClinicalTrials.gov ID
- NCT07132333
- Acronym / sponsor ID
- MEB@ZPM / 482/2022BO1
- Conditions
- Psoriasis (PsO), Psoriasis Arthritis, Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Spondylarthropathies
- Keywords
- chronic inflammatory diseases, personalized medicine
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 3,000 participants (estimated)
- Lead sponsor
- University Hospital TuebingenUniversity, hospital or other
- Collaborators
- University Hospital Freiburg, University Hospital Heidelberg, University Hospital Ulm
- Study start
- 16 Nov 2022 (actual)
- Primary completion
- Nov 2032 (estimated)
- Study completion
- Nov 2032 (estimated)
- First posted
- 20 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Molecular Inflammation Board at the Center for Personalized Medicine
Detailed description
Molecular Inflammation Board at the Center for Personalized Medicine
The study objectives are:
To ensure a prospective documentation of all patients who are referred to the Molecular Inflammation Board in routine clinical care To prospectively ensure the documentation of MEB patients with an emphasis to clinical outcome parameters and further response assessments (e.g. peripheral immunmonitoring, imaging parameters) To prospectively assess patient-reported outcome of MEB patients To evaluate compliance to MEB suggestions in routine clinical care
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 14 Months
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Patients with chronic inflammatory diseases and indication for therapy with biologic agents
Key inclusion criteria (3 listed)
- Chronic inflammatory disorder (PsO, PsA, SpA, IBD)
- Given informed consent
- 18 years of age
Key exclusion criteria (1 listed)
- No capacity to consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Biologic AgentIntervention with biologic agents | Biological | – |
Primary outcome
Therapy persistence
Time frame: Through study completion, an average of 1 year
Duration of intervention with biological agent
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Aug 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Psoriasis (PsO)
RecruitingPhase 4
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Psoriasis, Overweight or Obesity
RecruitingPhase 1
A Study of HL40626S Tablets in Healthy Adults
Skin Disease, Immune System Disease
RecruitingPhase 3
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
Plaque Psoriasis
Not yet recruiting
Definition of Novel Optoacoustic Biomarkers of Psoriasis and Psoriatic Arthritis
Psoriasis (PsO), Psoriasis Arthritis
Not yet recruitingObservational study
A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy
Plaque Psoriasis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Psoriasis (PsO) and Psoriasis Arthritis, run by University Hospital Tuebingen at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Nisar P Malek, Prof. Dr. (+4970712982722, zpm-meb@med.uni-tuebingen.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Therapy persistence (time frame: Through study completion, an average of 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Aug 2025.